At a glance

ClinicalIndex Comparison Record

Phase 2Unknown· 80 target

Drug / intervention

Paclitaxel +2 moredrug

Likely dose

Paclitaxel 175 mg/m2from record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02250599

NCT02250599Phase 2Unknown

Compare CT.gov

Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University·interventional·Posted Sep 26, 2014·Updated Dec 30, 2015

In Brief

A Phase 2 clinical trial evaluating Paclitaxel, Bevacizumab, and 1 other intervention for Nasopharyngeal Neoplasms. Targeting 80 participants across 8 sites.

Detailed Summary

The present study will be a randomized, control, multicenter phase II study of metastatic nasopharyngeal carcinoma (NPC) treated with evacizumab (AVASTIN,Roch) with paclitaxel and carboplatin regimen (TC+AVASTIN) or carboplatin/paclitaxel alone (TC). The population consists of metastatic nasopharyngeal carcinoma (NPC) that failed the radical radiotherapy or chemotherapy-naïve advanced NPC (stage IV). The effectiveness and side effects will be evaluated according to RECIST 1.1 and NCI-CTC AE V4.0.TEORTC QLQ-C30 and EORTC QLQ-H\&N35 are used to measure PRO outcome for this study.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNasopharyngeal Neoplasms

CountriesChina

Collaborators--

Timeline

Phase 2UnknownOverdue

201520162017201820192020202120222023202420252026

Enrollment StartAug 2014

First PostedSep 2014

Primary CompletionApr 2016

Study CompletionDec 2016

TodayJul 2026

First PostedSep 26, 2014

Enrollment StartAug 1, 2014

Primary CompletionApr 1, 2016

Study CompletionDec 1, 2016

TodayJul 1, 2026

Enrollment to primary: 1.7 yearsPosted 11.8 years ago

Interventions

Paclitaxeldrug

Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle

Bevacizumabdrug

Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle

Carboplatindrug

Carboplatin AUC 6 IV Day 1 each 3-week cycle